Intech Biopharm Corporation (TPEX:6461)
Taiwan · Delayed Price · Currency is TWD 15.90
-0.10 (-0.63%)
Aug 19, 2026, 1:30 PM CST
Intech Biopharm Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 48.55 | 107.53 | 39.78 | 25.85 | 23.65 | 38.9 | |
Revenue Growth | -57.87% | 170.31% | 53.90% | 9.30% | -39.21% | 84.30% |
Cost of Revenue | 234.22 | 218.47 | 197.4 | 189.84 | 170.91 | 158.27 |
Gross Profit | -185.67 | -110.94 | -157.63 | -164 | -147.26 | -119.37 |
Selling, General & Admin | 74.34 | 63.62 | 55.44 | 51.99 | 52.14 | 47.98 |
Research & Development | 205.05 | 189.94 | 143.06 | 104.49 | 118.68 | 126.63 |
Operating Expenses | 279.39 | 253.56 | 198.5 | 156.47 | 170.82 | 174.61 |
Operating Income | -465.06 | -364.5 | -356.13 | -320.47 | -318.08 | -293.98 |
Interest Expense | -32.24 | -33.52 | -34.16 | -33.59 | -23.04 | -19.54 |
Interest & Investment Income | 3.75 | 3.94 | 5.73 | 4.42 | 1.93 | 0.85 |
Currency Exchange Gain (Loss) | -0.46 | -0.46 | 0.03 | 0.04 | 0.18 | -0.08 |
Other Non Operating Income (Expenses) | 11.99 | 12.31 | 16.31 | 11.61 | 11.14 | 11 |
Pretax Income | -482.02 | -382.23 | -368.21 | -337.99 | -327.88 | -301.76 |
Income Tax Expense | - | 6.8 | - | - | - | - |
Net Income | -482.02 | -389.03 | -368.21 | -337.99 | -327.88 | -301.76 |
Net Income to Common | -482.02 | -389.03 | -368.21 | -337.99 | -327.88 | -301.76 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 170 | 152 | 137 | 120 | 116 | 102 |
Shares Outstanding (Diluted) | 170 | 152 | 137 | 120 | 116 | 102 |
Shares Change | 22.48% | 10.47% | 13.97% | 3.73% | 14.15% | 1.47% |
EPS (Basic) | -2.84 | -2.57 | -2.68 | -2.81 | -2.82 | -2.97 |
EPS (Diluted) | -2.84 | -2.57 | -2.68 | -2.81 | -2.82 | -2.97 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -401.57 | -423.02 | -312.84 | -234.17 | -201.13 | -221.91 |
Free Cash Flow Per Share | -2.37 | -2.79 | -2.28 | -1.94 | -1.73 | -2.18 |
Gross Margin | - | -103.18% | - | - | - | - |
Operating Margin | -957.88% | -338.99% | -895.26% | -1239.87% | -1345.12% | -755.76% |
Profit Margin | -992.81% | -361.80% | -925.63% | -1307.64% | -1386.55% | -775.74% |
Free Cash Flow Margin | -827.11% | -393.41% | -786.44% | -905.98% | -850.56% | -570.48% |
EBITDA | -373.96 | -274.52 | -269.8 | -235.74 | -232.8 | -208.82 |
EBITDA Margin | - | -255.31% | - | - | - | - |
D&A For EBITDA | 91.1 | 89.98 | 86.33 | 84.73 | 85.28 | 85.16 |
EBIT | -465.06 | -364.5 | -356.13 | -320.47 | -318.08 | -293.98 |